
Sign up to save your podcasts
Or


Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.
By Retina Synthesis4.5
88 ratings
Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.

43 Listeners

18 Listeners

100 Listeners

111,948 Listeners

56,508 Listeners

5 Listeners

9,532 Listeners

11 Listeners

47,654 Listeners

50 Listeners

11 Listeners

466 Listeners

19 Listeners

0 Listeners